Institution of basal-bolus therapy at diagnosis for children with type 1 diabetes mellitus

Pediatrics

Volumn 123, Issue 4, 2009, Pages

  Adhikari, Soumya ^a   Adams Huet, Beverley ^b   Wang, Yu Chi A ^a   Marks, James F ^a   White, Perrin C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Glargine; Glycemic control; Hemoglobin A1c; Honeymoon; Pediatric

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADOLESCENT; ARTICLE; CHILD; CONTROL GROUP; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; STATISTICAL MODEL; TREATMENT DURATION; TREATMENT OUTCOME; GLUCOSE BLOOD LEVEL; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY;

BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65349091293     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-3027     Document Type: Article

References (26)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986 (Pubitemid 23307905)
2. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003;25(6):1541-1577 (Pubitemid 36801936)
3. Dixon B, Peter Chase H, Burdick J, et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes. 2005;6(3):150-154 (Pubitemid 41223240)
4. Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004;6(5):589-595 (Pubitemid 39383065)
5. Hershon KS, Blevins TC, Mayo CA, Rosskamp R. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract. 2004;10(1):10-17
6. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev. 2005;21(6):545-553 (Pubitemid 41646014)
7. Päivärinta M, Tapanainen P, Veijola R. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2008;9(3):83-90
8. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23(11):1666-1671
9. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23(5):639-643 (Pubitemid 30321544)
10. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care. 2000;23(8):1137-1142 (Pubitemid 30616802)
11. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15(4):369-376 (Pubitemid 34704801)
12. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J. 2005;35(9):536-542 (Pubitemid 41291382)
13. Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics. 2008;121(3). Available at: www.pediatrics.org/cgi/content/full/121/3/e466
14. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care. 2000;23(2):157-162 (Pubitemid 30071017)
15. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med. 2004;21(11):1213-1220 (Pubitemid 39472377)
16. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapidacting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003;26(5):1490-1496 (Pubitemid 36929184)
17. Aly T, Devendra D, Eisenbarth GS. Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes. Am J Ther. 2005;12(6):481-490 (Pubitemid 41689748)
18. Goudy KS, Tisch R. Immunotherapy for the prevention and treatment of type 1 diabetes. Int Rev Immunol. 2005;24(5-6):307-326 (Pubitemid 41755150)
19. Greenbaum CJ. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. Clin Immunol. 2002;104(2):97-104
20. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54(6):1763-1769 (Pubitemid 40770766)
21. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692-1698 (Pubitemid 34547482)
22. Littell RC, Milliken GA, Stroup WW, Wolfinger RD, Schabenberger O. SAS for Mixed Models. 2nd ed. Cary, NC: SAS Institute; 2006
23. Knip M, Sakkinen A, Huttunen NP, et al. Postinitial remission in diabetic children: an analysis of 178 cases. Acta Paediatr Scand. 1982;71(6):901-908
24. Lombardo F, Valenzise M, Wasniewska M, et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin-dependent diabetes mellitus: the key role of age at diagnosis. Diabetes Nutr Metab. 2002;15(4):246-251 (Pubitemid 35189809)
25. Diabetes Control and Complications Trial Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab. 1987;65(1):30-36 (Pubitemid 17092084)
26. Daneman D, Clarson C. Residual β-cell function in children with type 1 diabetes: measurement and impact on glycemic control. Clin Invest Med. 1987;10(5):484-487 (Pubitemid 18025766)